Pharmafile Logo

TVF Communications

- PMLiVE

BeiGene’s Tevimbra combination granted FDA approval to treat gastric cancer

Approximately 27,000 cases of the disease were diagnosed in the US in 2024

- PMLiVE

Novartis’ investigational spinal muscular atrophy gene therapy shows promise in late-stage study

An estimated one in 10,000 infants globally are affected by the rare neuromuscular disease

- PMLiVE

J&J’s Rybrevant/Lazcluze combination approved by EC for EGFR-mutated lung cancer

Alterations in EGFR are among the most common driver mutations in NSCLC patients

- PMLiVE

Merck’s Winrevair granted MHRA approval to treat pulmonary arterial hypertension

The drug has been authorised for use in adults with moderate or marked limitations of physical activity

- PMLiVE

New Webinar: The 2025 Pharma Toolkit for Virtual Medical Education

Elevate your MedEd strategy with our 2025 toolkit! From AI-driven patient avatars to interactive augmented reality scenarios, learn about the hottest new virtual tools that are setting the standard for...

Impetus Digital

Optimize your Medical Education Strategy: Insights from Wiley’s 2024 HCPs’ Information Seeking Behavior Study

- PMLiVE

Optimize your Medical Education Strategy: Insights from Wiley’s 2024 HCPs’ Information Seeking Behavior Study

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to elevate the impact of your medical education efforts in the latest Medical...

Wiley

- PMLiVE

Pfizer’s Braftovi regimen receives FDA accelerated approval to treat colorectal cancer

The disease is the third most common type of cancer globally

- PMLiVE

AstraZeneca’s Tagrisso granted EC approval in EGFR-mutated lung cancer

More than 450,000 people are diagnosed with lung cancer each year in Europe

- PMLiVE

Launching a novel drug treatment in Japan

Critical insights to prepare for market access success

- PMLiVE

The importance of caregivers in the patient journey

Caregivers often play an integral role during interactions with medical professionals

- PMLiVE

Novo Nordisk invests $1.2bn to establish rare disease production facility in Denmark

The site will be designed to accommodate multiple product types within rare diseases

- PMLiVE

Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

The rare liver disease affects approximately 15 per 100,000 people in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links